Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors

Leukemia

Volumn 23, Issue 1, 2009, Pages 162-169

  Negaard, H F S ^a,b   Iversen, N ^a   Bowitz Lothe, I M ^a   Sandset, P M ^a,b   Steinsvik, B ^a   Ostenstad B ^a   Iversen, P O ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW MICROVASCULAR DENSITY; CANCER REGRESSION; CANCER STAGING; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

EID: 58249119700     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.255     Document Type: Article

References (45)

1. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
2. Niemoller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O et al Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003; 129: 234-238.
3. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D et al Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002; 100: 3344-3351.
4. Bhatti SS, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 2006; 81: 649-656.
5. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 2007; 62: 105-118.
6. He Y, Chang G, Zhan S, Song X, Wang X, Luo Y. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem Biophys Res Commun 2008; 370: 489-494.
7. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001; 276: 12241-12248.
8. Cancer Registry of Norway. Cancer in Norway 2006 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway: Oslo, 2007, p 49.
9. Negaard H, Dahm A, Sandset PM, Iversen PO, Ostenstad B. Angiogenesis and hemostasis in hematological neoplasias. Curr Drug Targets 2005; 6: 683-699.
10. Dirkx AEM, Oude Egbrink MGA, Wagstaff J, Griffioen AW. Monocyte/ macrophage infiltration in tumors: Modulators of angiogenesis. J Leukoc Biol 2006; 80: 1183-1196.
11. Negaard HFS, Iversen PO, Ostenstad B, Iversen N, Holme PA, Sandset PM. Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. Thromb Haemost 2008; 99 1040-1048.
12. WHO. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 3rd edn. IARC Press: Lyon, 2001.
13. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P et al Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294-317.
14. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005; 132: 410-451.
15. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48 198-206.
16. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
17. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
18. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
20. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, Mcculloch P et al Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32: 2474-2484.
21. Bendz B, Andersen TO, Sandset PM. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res 2000; 97: 463-472.
22. Applied Biosystems. Relative quantification of gene expression. ABI Prism 7700 Sequence Detection System. User Bulletin No. 2. 1997.
23. Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. APMIS 2004; 112: 413-430.
24. Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004; 89: 391-402.
25. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216.
26. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R et al Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004; 34: 235-239.
27. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006; 6 626-635.
28. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-174.
29. Aguayo A, Kantarjian H, Estey E, Giles FJ, Verstovsek S, Manshouri T et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923-1930.
30. Gora-Tybor J, Blonski JZ, Robak T. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw 2005; 16: 41-46.
31. Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003; 82: 19-23.
32. Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002; 68: 91-100.
33. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood 2000; 96: 3712-3718.
34. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256-263.
35. Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 2002; 95: 1071-1075.
36. Rosinol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M et al Response to thalidomide in multiple myeloma: Impact of angiogenic factors. Cytokine 2004; 26: 145-148.
37. Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke KD et al Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66: 83-88.
38. Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K et al Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm 2005; 2005 171-174.
39. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003; 120: 452-456.
40. Tomita M, Semenza GL, Michiels C, Matsuda T, Uchihara JN, Okudaira T et al. Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells. Biochem J 2007; 406: 317-323.
41. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137-165.
42. Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP. The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours. Mol Pathol 1998; 51: 273-276.
43. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
44. Bruserud O, Ryningen A, Olsnes AM, Stordrange L, Oyan AM, Kalland KH et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007; 92: 332-341.
45. Aref S, Salama O, Shamaa S, El-Refaie M, Mourkos H. Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology 2007; 12: 319-324.